Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas

References

• Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab. 1996;81:2338–43.
   PubMed Web of Science ®Google Scholar
• Ciccarelli E, Grottoli S, Razzore P, Gaia D, Bertagna A, Cirillo S, et al. Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinemia and outcome of drug-induced pregnancy. J Endocrinol Invest. 1997;20:547–51.
   PubMed Web of Science ®Google Scholar
• Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab. 1997;82:876–83.
   PubMed Web of Science ®Google Scholar
• Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, et al. Longterm and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab. 1997;82:3574–9.
   PubMed Web of Science ®Google Scholar
• Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab. 2004;89:1704–11.
   PubMed Web of Science ®Google Scholar
• Delgrange E, Maiter D, Donckier J. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur J Endocrinol. 1996;134:454–6.
   PubMed Web of Science ®Google Scholar
• Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab. 2001;86:5256–61.
   PubMed Web of Science ®Google Scholar
• Ferrari C, Paracchi A, Mattei AM, de Vincentiis S, D’Alberton A, Crosignani P. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol (Copenh). 1992;126:489–94.
   PubMedGoogle Scholar
• Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T, et al. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol. 1997;46:409–13.
   PubMed Web of Science ®Google Scholar
• Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab. 1985;60:698–705.
   PubMed Web of Science ®Google Scholar
• Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest. 1997;20:537–46.
   PubMed Web of Science ®Google Scholar
• Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R, et al. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab. 2010;95:2672–9.
   PubMed Web of Science ®Google Scholar
• Shimon I, Benbassat L, Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of men. Eur J Endocrinol. 2007;156:225–31.
   PubMed Web of Science ®Google Scholar
• Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999;84:2518–22.
   PubMed Web of Science ®Google Scholar
• Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med. 1994;331:904–9.
   PubMed Web of Science ®Google Scholar
• Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273–88.
   PubMed Web of Science ®Google Scholar
• Delgrange E, Duprez T, Maiter D. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy. Clin Endocrinol. 2006;64:456–62.
   PubMed Web of Science ®Google Scholar
• Lundin P, Bergström K, Nyman R, Lundberg PO, Muhr C. Macroprolactinomas: serial MR imaging in long-term bromocriptine therapy. Am J Neuroradiol. 1992;13:1279–91.
   PubMed Web of Science ®Google Scholar
• Manuchehri AM, Sathyapalan T, Lowry M, Turnbull LW, Rowland-Hill C, Atkin SL. Effect of dopamine agonists on prolactiomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). Pituitary. 2007;10:261–6.
   PubMed Web of Science ®Google Scholar
• Vaneckova M, Seidl Z, Hana V, Jarkovska Z. Macroprolactinomas: retrospective follow up study in the MR imaging and correlation with clinical symptomatology. Neuroendocrinol Lett. 2007;28:841–5.
   PubMed Web of Science ®Google Scholar
• Yousem DM, Arrington JA, Zinreich SJ, Kumar AJ, Bryan RN. Pituitary asenomas: possible role of bromocriptine in intratumoral hemorrhage. Radiology. 1989;170:239–43.
   PubMed Web of Science ®Google Scholar
• Bernstein MA, Huston J III, Lin C, Gibbs GF, Felmlee JP. High-resolution intracranial and cervical MRA at 3·0T: technical considerations and initial experience. Magn Reson Med. 2001;46:955–62.
   PubMed Web of Science ®Google Scholar
• Kakite S, Fujii S, Kurosaki M, Kanasaki Y, Matsusue E, Kaminou T, et al. Three-dimensional gradient echo versus spin echo sequence in contrast-enhanced imaging of the pituitary gland at 3T. Eur J Radiol. 2011;79:108–12.
   PubMed Web of Science ®Google Scholar
• Kurosaki M, Tabuchi S, Akatsuka K, Kamitani H, Watanabe T. Application of phase sensitive imaging (PSI) for hemorrhage diagnosis in pituitary adenomas. Neurol Res. 2010;32:614–9.
   PubMed Web of Science ®Google Scholar
• Pinker K, Ba-Ssalamah A, Wolfsberger S, Mlynarik V, Knosp E, Trattnig S. The value of highfield MRI (3 T) in the assessment of sellar lesions. Eur J Radiol. 2005;54:327–34.
   PubMed Web of Science ®Google Scholar
• Wolfsberger S, Ba-Ssalamah A, Pinker K, Mlynárik V, Czech T, Knosp E, et al. Application of three-tesla magnetic resonance imaging for diagnosis and surgery of sellar lesions. J Neurosurg. 2004;100:278–86.
   PubMed Web of Science ®Google Scholar
• Di Chiro G, Nelson KB. The volume of the sella turcica. Am J Radiol. 1962;87:989–1008.
   Web of Science ®Google Scholar
• Asa SL. Adenomas causing prolactin excess. In: Silverberg S G, editor. Atlas of tumor pathology, 4th ser. Fasc 15. Washington DC: AFIP; 2011. p. 93–108.
   Google Scholar
• Saitoh Y, Mori H, Matsumoto K, Ushio Y, Hayakawa T, Mori S, et al. Accumulation of amyloid in pituitary adenomas. Acta Neuropathol. 1985;68:87–92.
   PubMed Web of Science ®Google Scholar
• Hagiwara A, Inoue Y, Wakasa K, Haba T, Tashiro T, Miyamoto T. Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology. 2003;228:533–8.
   PubMed Web of Science ®Google Scholar
• Tosaka M, Sato N, Hirato J, Fujimaki H, Yamaguchi R, Kohga H, et al. Assessment of hemorrhage in pituitary macroadenoma by T2*-weighted gradient-echo MR imaging. Am J Neuroradiol. 2004;28:2023–9.
   Web of Science ®Google Scholar